Bioprinting and Cellular Therapies for Type 1 Diabetes

Dino Ravnic, Ashley N. Leberfinger, Ibrahim Tarik Ozbolat

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Type 1 diabetes mellitus is a chronic autoimmune disease that results from the destruction of beta (β) cells in the pancreatic islets, leading to loss of insulin production and resultant hyperglycemia. Recent developments in stem cell biology have generated much excitement for β-cell replacement strategies; β cells are one of many cell types in the complex islet environment and pancreas. In this Opinion, we discuss recent successful attempts to generate β cells and how this can be coupled with bioprinting technologies in order to fabricate pancreas tissues, which holds great potential for type 1 diabetes. Possibilities of integrating vascularization and encapsulation in bioprinted tissues are expounded, and future prospects, such as pancreas-on-a-chip, are also presented. Improving the transformation of stem cells to functional β cells and other pancreatic cells will speed up the development of cell-based bioprinting-enabled therapies for type 1 diabetes. Bioprinting for tissue and organ fabrication has the advantages of precise component deposition, controllable construct size and anatomical geometry, biomimetic cellular organization and interactions, integration of vasculature or vascular network, and high-throughput capability. Combining bioprinting with encapsulation of pancreatic tissues may be necessary for protection of constructs from the immune system. Integration of encapsulated vascularized pancreatic islets into a scale-up perfusable pancreatic organ will be promising for type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1025-1034
Number of pages10
JournalTrends in Biotechnology
Volume35
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Bioprinting
Medical problems
Type 1 Diabetes Mellitus
Tissue
Stem cells
Encapsulation
Cytology
Pancreas
Immune system
Insulin
Biomimetics
Therapeutics
Islets of Langerhans
Stem Cells
Throughput
Fabrication
Geometry
Hyperglycemia
Autoimmune Diseases
Blood Vessels

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering

Cite this

@article{b2289cb9ea454ed7ab7e095fa676c5de,
title = "Bioprinting and Cellular Therapies for Type 1 Diabetes",
abstract = "Type 1 diabetes mellitus is a chronic autoimmune disease that results from the destruction of beta (β) cells in the pancreatic islets, leading to loss of insulin production and resultant hyperglycemia. Recent developments in stem cell biology have generated much excitement for β-cell replacement strategies; β cells are one of many cell types in the complex islet environment and pancreas. In this Opinion, we discuss recent successful attempts to generate β cells and how this can be coupled with bioprinting technologies in order to fabricate pancreas tissues, which holds great potential for type 1 diabetes. Possibilities of integrating vascularization and encapsulation in bioprinted tissues are expounded, and future prospects, such as pancreas-on-a-chip, are also presented. Improving the transformation of stem cells to functional β cells and other pancreatic cells will speed up the development of cell-based bioprinting-enabled therapies for type 1 diabetes. Bioprinting for tissue and organ fabrication has the advantages of precise component deposition, controllable construct size and anatomical geometry, biomimetic cellular organization and interactions, integration of vasculature or vascular network, and high-throughput capability. Combining bioprinting with encapsulation of pancreatic tissues may be necessary for protection of constructs from the immune system. Integration of encapsulated vascularized pancreatic islets into a scale-up perfusable pancreatic organ will be promising for type 1 diabetes.",
author = "Dino Ravnic and Leberfinger, {Ashley N.} and Ozbolat, {Ibrahim Tarik}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.tibtech.2017.07.006",
language = "English (US)",
volume = "35",
pages = "1025--1034",
journal = "Trends in Biotechnology",
issn = "0167-7799",
publisher = "Elsevier Limited",
number = "11",

}

Bioprinting and Cellular Therapies for Type 1 Diabetes. / Ravnic, Dino; Leberfinger, Ashley N.; Ozbolat, Ibrahim Tarik.

In: Trends in Biotechnology, Vol. 35, No. 11, 01.11.2017, p. 1025-1034.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bioprinting and Cellular Therapies for Type 1 Diabetes

AU - Ravnic, Dino

AU - Leberfinger, Ashley N.

AU - Ozbolat, Ibrahim Tarik

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Type 1 diabetes mellitus is a chronic autoimmune disease that results from the destruction of beta (β) cells in the pancreatic islets, leading to loss of insulin production and resultant hyperglycemia. Recent developments in stem cell biology have generated much excitement for β-cell replacement strategies; β cells are one of many cell types in the complex islet environment and pancreas. In this Opinion, we discuss recent successful attempts to generate β cells and how this can be coupled with bioprinting technologies in order to fabricate pancreas tissues, which holds great potential for type 1 diabetes. Possibilities of integrating vascularization and encapsulation in bioprinted tissues are expounded, and future prospects, such as pancreas-on-a-chip, are also presented. Improving the transformation of stem cells to functional β cells and other pancreatic cells will speed up the development of cell-based bioprinting-enabled therapies for type 1 diabetes. Bioprinting for tissue and organ fabrication has the advantages of precise component deposition, controllable construct size and anatomical geometry, biomimetic cellular organization and interactions, integration of vasculature or vascular network, and high-throughput capability. Combining bioprinting with encapsulation of pancreatic tissues may be necessary for protection of constructs from the immune system. Integration of encapsulated vascularized pancreatic islets into a scale-up perfusable pancreatic organ will be promising for type 1 diabetes.

AB - Type 1 diabetes mellitus is a chronic autoimmune disease that results from the destruction of beta (β) cells in the pancreatic islets, leading to loss of insulin production and resultant hyperglycemia. Recent developments in stem cell biology have generated much excitement for β-cell replacement strategies; β cells are one of many cell types in the complex islet environment and pancreas. In this Opinion, we discuss recent successful attempts to generate β cells and how this can be coupled with bioprinting technologies in order to fabricate pancreas tissues, which holds great potential for type 1 diabetes. Possibilities of integrating vascularization and encapsulation in bioprinted tissues are expounded, and future prospects, such as pancreas-on-a-chip, are also presented. Improving the transformation of stem cells to functional β cells and other pancreatic cells will speed up the development of cell-based bioprinting-enabled therapies for type 1 diabetes. Bioprinting for tissue and organ fabrication has the advantages of precise component deposition, controllable construct size and anatomical geometry, biomimetic cellular organization and interactions, integration of vasculature or vascular network, and high-throughput capability. Combining bioprinting with encapsulation of pancreatic tissues may be necessary for protection of constructs from the immune system. Integration of encapsulated vascularized pancreatic islets into a scale-up perfusable pancreatic organ will be promising for type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85026797136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026797136&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2017.07.006

DO - 10.1016/j.tibtech.2017.07.006

M3 - Review article

C2 - 28789815

AN - SCOPUS:85026797136

VL - 35

SP - 1025

EP - 1034

JO - Trends in Biotechnology

JF - Trends in Biotechnology

SN - 0167-7799

IS - 11

ER -